Firms

Faber

Europe

faber.vc

signal.nfx.com

goldi.ai

Faber is a Lisbon-based early-stage venture capital firm investing in teams transforming the world with frontier technology, with a focus on deep tech across AI/ML, climate and ocean tech, robotics, and biotech. The firm targets pre-seed and seed-stage startups across Southern Europe.

Founded: 2012
Type: Venture capital

Funds3

Faber Tech III2024-11-042024-11-04€31M
FIRSTCLOSEEUR31M targetEUR60M; finalclosenotverified.
Faber Blue Pioneers I2022-06-272022-06-27€32M
FIRSTCLOSEEUR32M originaltargetEUR30M, laterEUR35Mtargetlead unresolved, notfinalsize.
Faber Tech II2020-11-202020-11-20€20M
FIRSTCLOSEEUR20.5M targetEUR30M, finalsizeunknown.

Team

Investments

team@apexlogos.ai6 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size and status | Vehicle | Amount and status | Dated evidence and qualification | | --- | --- | --- | | Faber Tech III | **€31m first close; €60m target** | [LP NATO Innovation Fund announcement, 2024-11-04](https://www.nif.fund/news/nato-innovation-fund-invests-in-faber-marking-first-investment-in-a-southern-european-fund/). EIF anchored, alongside NIF and Caixa Capital. Newer-fund/final-close searches on 2026-10-06 did not establish a subsequent final close. This is the latest-known launch in checked sources. | | Faber Blue Pioneers I | **€32m first close**, exceeding original **€30m target** | [Tech.eu, 2022-06-27](https://tech.eu/2022/06/27/fabers-new-oceanclimate-focused-deep-tech-fund-already-oversubscribed-at-eur32-million/). Ocean/climate deep-tech vehicle, targeting 20–25 companies. [Faber's own LinkedIn announcement](https://www.linkedin.com/posts/faber-vc_lisbon-based-faber-closes-climate-focused-activity-6947164998603309056-b_yt/) corroborates €32m first close; precise calendar date not exposed in retrieved post. Final size not established here. | | Faber Tech II | **€20.5m first close; €30m target** | [Faber announcement, 2020-11-20](https://faber-vc.medium.com/announcing-faber-tech-ii-5183c77b2407). AI/data-driven Southern European pre-Series A strategy. Final fundraising close/committed size not established here. | | Original investment vehicle | Approximately **€500k initially**, growing to approximately **€11m** | Same [2020-11-20 firm history](https://faber-vc.medium.com/announcing-faber-tech-ii-5183c77b2407) describes an operating company funded by repeated capital increases, not a conventional €11m closed fund. | Do not sum these historic closes/targets into current AUM. Current firm-wide AUM was not verified. The [Banco de España investment-fund register](https://www.bde.es/webbe/en/estadisticas/otras-clasificaciones/clasificacion-entidades/listas-instituciones-financieras/listas-fondos-inversion-pais/lista-if-pt.html) lists these vehicles as closed investment-fund structures; that classification does not prove fundraising final close or a final committed amount. A [2024 blue-economy report](https://medblueconomyplatform.org/wp-content/uploads/2024/04/report_blue_invest_final_7march-compressed.pdf) lists Blue Pioneers' target at €35m, differing from its original €30m target. It is a later target lead, not verified final closing evidence. All undated sources accessed 2026-10-06. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | Faber Tech II | EUR 20500000 | 2020-11-20 | | Faber Blue Pioneers I | EUR 32000000 | 2022-06-27 | | Faber Tech III | EUR 31000000 | 2024-11-04 |
team@apexlogos.ai7 hours ago
Match research 2026-10-06 / Faber / sha256:845af62a4e95da07b98ff9f297ea39282977fbe90a514cea99ff06b691731b72 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **Luminate / Luminate Medical** | Oncology devices including home infusion/monitoring systems and chemotherapy-side-effect prevention products. Scientific medical-device work is distinct from ordinary care-services software. | [ARTIS Ventures press release on GlobeNewswire, 2026-01-07](https://www.globenewswire.com/news-release/2026/01/07/3214500/30232/en/Luminate-Raises-21-Million-in-Funding-to-Expand-Home-Cancer-Treatment.html): **$21m expanded Series A**, ARTIS and Lachy Groom co-led; Faber named among participating existing investors. No Faber-specific check or named vehicle. [Current official site](https://www.luminatemed.com/) corroborates the home oncology platform (undated; accessed 2026-10-06). | These are substantive verified examples, not an exhaustive portfolio audit. Other snapshot candidates such as Yplasma, Zymvol, MicroHarvest, Smartex and Mitiga remain additional leads; their presence alone should not convert every software company in the portfolio into deep tech. ## Neurotech and adjacent investments **No verified neurotech investment found in the sources checked**, using direct neural recording, stimulation, brain interfaces or comparable nervous-system technology as the threshold. Searches covered Faber neurotech/brain terms, its website/focus/portfolio, saved investments and the two strongest adjacent candidates below. This is a search outcome, not a claim that the firm has never invested in neurotechnology. - **iLoF — neuroscience/diagnostic adjacency.** Its optical blood-profiling platform has Alzheimer's clinical-trial screening applications, and the company lists a 2023 Roche-supported Alzheimer's pilot. Its verified Faber-led 2022 financing is above. The [official company description](https://ilof.tech/about) and [EIT Health explanation, 2022-07-28](https://eithealth.eu/news-article/wildcard-winner-ilof-secures-further-5m-investment/) establish photonics/AI and neurological-disease relevance, not direct neural recording or stimulation. Record as neuro-adjacent diagnostics rather than a verified BCI/neurotech investment. - **Luminate — peripheral-neuropathy-prevention adjacency.** The [2026-01-07 ARTIS release](https://www.globenewswire.com/news-release/2026/01/07/3214500/30232/en/Luminate-Raises-21-Million-in-Funding-to-Expand-Home-Cancer-Treatment.html) describes Lilac/Lily devices targeting neuropathy and hair-loss side effects of cancer drugs. Neuropathy is relevant to peripheral nerves, but this source does not establish a neural interface or neuromodulation mechanism. A later reviewer using a broad nervous-system-device definition may classify it differently after checking Lilac's mechanism. Do not treat home infusion itself as neurotech. ## Conflicts, missing information and later Adex review 1. **Fund close versus target:** retain Tech III €31m initial close, €60m target and 2024-11-04 announcement separately. Find a primary final-close announcement before updating a final-size field. Tech II and Blue Pioneers final sizes remain unresolved; the later €35m Blue Pioneers target needs reconciliation. 2. **iLoF funding composition:** [EU-Startups, 2022-07-28](https://www.eu-startups.com/2022/07/digital-health-startup-ilof-secures-e4-89-million-to-accelerate-personalised-drug-discovery/) splits the package into approximately €4m equity and €880k ERDF grant, while its wording mixes euro and dollar units and headline is €4.89m. EIT Health calls the package $5m. Do not record $5m as entirely private equity or as Faber's check; exact equity currency/amount should be resolved with original company funding documentation. 3. **Hefring participation correction:** snapshot marks Faber non-lead with missing amount/date and seed label; official release establishes **lead**, **€2.2m**, **2024-05-21**, while not explicitly validating seed stage. 4. **Alias review:** snapshot has both Luminate and Luminate Medical; PHOTON IP and Photon Bridge; Mitiga Solutions and MITIGA SOLUTIONS SL; Annea and Annea Ai. Review entity mapping and round duplication before importing research. PHOTON IP/Photon Bridge release offers particularly strong alias evidence. 5. **People attribution:** snapshot contains many external job titles under Faber roles (e.g. portfolio-company founders and scientific/industry advisers). Do not assume they are investment partners or employees. Verify current role type/team against official team documentation separately; Signal's retrieved team section was empty. 6. **2012/2013 foundation:** primary firm history and company press-release boilerplate use different milestones. Legal incorporation was not checked. 7. **Missing deal precision:** Faber check amounts, ownership, named investing vehicle, exact subscription dates, current AUM and exhaustive neurotech coverage were not established. Publication dates are not guaranteed legal closing dates. All cited web pages were checked/accessed **2026-10-06**. Publication dates are stated alongside claims where available; undated homepage, company timeline, Signal and registers use that access date. Saved Adex evidence and Signal are baseline references; verification rests on official firm/company/LP evidence and named reporting. This file supports a later Adex review and authorizes no database mutation.
team@apexlogos.ai7 hours ago
Match research 2026-10-06 / Faber / sha256:845af62a4e95da07b98ff9f297ea39282977fbe90a514cea99ff06b691731b72 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # Faber — Match firm research - **Exact ID:** `Faber`. - **Adex URL:** https://adex.page/firms/Faber - **Research date:** 2026-10-06. - **Status:** complete for this research pass; unresolved items are explicitly listed below. Research only; no Adex/database updates made. Faber is a Lisbon-based specialist venture firm investing at the intersection of science and technology. Verified examples include photonic chips, spacecraft propulsion, optical biological profiling and maritime sensing/decision systems. Its initial-investment mandate is pre-seed/seed, with support through Series A. Fund sizes must remain separate: latest-known Tech III announcement establishes a €31m initial close and €60m target, not a €60m final close. No verified direct neurotech investment was found; iLoF and Luminate are relevant adjacent cases with substantial classification caveats. ## Starting evidence and identity The saved exact-ID MCP snapshot, `data/research/_sources/Faber.adex.json`, was retrieved 2026-10-06 at 19:29:32 UTC. It identifies Faber, founded 2012, with a Southern European deep-tech/pre-seed/seed description, no investor check-size values, and 31 investment participation rows. Named examples include iLoF, Sword Health, Luminate/Luminate Medical, ISPTech, PHOTON IP/Photon Bridge, Hefring Marine, Yplasma, Zymvol, Poseidona and Mitiga. These are starting claims, not verification. Several records have null announcement dates and round amounts; company aliases and separate participation rows require review. [NFX Signal: Faber Ventures](https://signal.nfx.com/firms/faber-ventures), directly read 2026-10-06, gives Europe as the location and displays co-investor suggestions including BlueYard Capital, Passion Capital and FoodLabs. Retrieved text has no usable investor team profiles, stage detail, check size, fund size or transaction list. Its co-investor suggestions do not establish any named round or independent confirmation of Adex claims. The [official website](https://www.faber.vc/) lists a Lisbon address and current strategy. Faber's [own history, published 2020-11-20](https://faber-vc.medium.com/announcing-faber-tech-ii-5183c77b2407), places its beginnings around 2012 and core-team/investment formation in 2013. A [Hefring release, 2024-05-21](https://www.hefringmarine.com/resources/news/hefring-raises-euro-2m-in-funding-to-accelerate-growth), calls Faber established in 2013. Treat 2012 versus 2013 as inception versus operational-start ambiguity rather than a confidently resolved legal-incorporation date. This is Faber/Faber Ventures at faber.vc; unrelated Faber Group logistics and industrial businesses are excluded. ## Fund size and status | Vehicle | Amount and status | Dated evidence and qualification | | --- | --- | --- | | Faber Tech III | **€31m first close; €60m target** | [LP NATO Innovation Fund announcement, 2024-11-04](https://www.nif.fund/news/nato-innovation-fund-invests-in-faber-marking-first-investment-in-a-southern-european-fund/). EIF anchored, alongside NIF and Caixa Capital. Newer-fund/final-close searches on 2026-10-06 did not establish a subsequent final close. This is the latest-known launch in checked sources. | | Faber Blue Pioneers I | **€32m first close**, exceeding original **€30m target** | [Tech.eu, 2022-06-27](https://tech.eu/2022/06/27/fabers-new-oceanclimate-focused-deep-tech-fund-already-oversubscribed-at-eur32-million/). Ocean/climate deep-tech vehicle, targeting 20–25 companies. [Faber's own LinkedIn announcement](https://www.linkedin.com/posts/faber-vc_lisbon-based-faber-closes-climate-focused-activity-6947164998603309056-b_yt/) corroborates €32m first close; precise calendar date not exposed in retrieved post. Final size not established here. | | Faber Tech II | **€20.5m first close; €30m target** | [Faber announcement, 2020-11-20](https://faber-vc.medium.com/announcing-faber-tech-ii-5183c77b2407). AI/data-driven Southern European pre-Series A strategy. Final fundraising close/committed size not established here. | | Original investment vehicle | Approximately **€500k initially**, growing to approximately **€11m** | Same [2020-11-20 firm history](https://faber-vc.medium.com/announcing-faber-tech-ii-5183c77b2407) describes an operating company funded by repeated capital increases, not a conventional €11m closed fund. | Do not sum these historic closes/targets into current AUM. Current firm-wide AUM was not verified. The [Banco de España investment-fund register](https://www.bde.es/webbe/en/estadisticas/otras-clasificaciones/clasificacion-entidades/listas-instituciones-financieras/listas-fondos-inversion-pais/lista-if-pt.html) lists these vehicles as closed investment-fund structures; that classification does not prove fundraising final close or a final committed amount. A [2024 blue-economy report](https://medblueconomyplatform.org/wp-content/uploads/2024/04/report_blue_invest_final_7march-compressed.pdf) lists Blue Pioneers' target at €35m, differing from its original €30m target. It is a later target lead, not verified final closing evidence. All undated sources accessed 2026-10-06. ## Investment stages and check size The [official homepage](https://www.faber.vc/) explicitly gives **pre-seed and seed**, first tickets **up to €2.5m**, and Southern Europe with selective wider European investments. It separately describes supporting companies from pre-seed to Series A. There is no verified current minimum or typical check. [Tech III's LP announcement, 2024-11-04](https://www.nif.fund/news/nato-innovation-fund-invests-in-faber-marking-first-investment-in-a-southern-european-fund/) supports pre-seed/seed in applied science and digital transformation: vertical AI/governance, robotics, computational biology/chemistry, data infrastructure and novel computation. [Tech.eu, 2022-06-27](https://tech.eu/2022/06/27/fabers-new-oceanclimate-focused-deep-tech-fund-already-oversubscribed-at-eur32-million/) gives Blue Pioneers historical checks €100k–€1.5m and pre-Series A investing; keep that fund-specific historical range distinct from today's firm-level cap. Historical Series A participation below is not evidence of a general growth-stage mandate. ## Named previous deep-tech investments Round amounts below are company-round totals, not Faber check amounts. Sources attribute Faber/Faber Ventures directly; none of these attributions is inferred from a partner's earlier employment. | Company | Technology rationale | Verified attribution, round/date and supporting URL | | --- | --- | --- | | **PHOTON IP / Photon Bridge** | Integration of silicon photonics with active III-V materials for low-power optical chips; hardware/materials engineering. | Company [release, 2025-01-13](https://www.photonbridge.com/news/photon-ip-raises-%E2%82%AC4.75m-seed-funding-led-by-innovation-industries,-with-faber,-bom-and-photondelta): **€4.75m seed**, Innovation Industries led; Faber participated with BOM and PhotonDelta support. Release retains PHOTON IP name on current Photon Bridge website. | | **ISPTech** | DLR-derived spacecraft propulsion; patented hydrogen-peroxide/ionic-liquid propellant technology and multimode propulsion. | Company [release, page dated 2026-02-27, dateline 2026-02-25](https://www.isptech.space/news/isptech-raises-e5-5m-seed-round-to-redefine-how-spacecraft-manoeuvre-in-orbit): **€5.5m seed**, Join Capital led, Faber participated. Date discrepancy is two days within same announcement; do not silently choose one as exact transaction date. | | **Hefring Marine** | On-board vessel sensing/data analysis and AI-based decision support for speed, routing, safety and maintenance; maritime cyberphysical system. | Company [release, 2024-05-21](https://www.hefringmarine.com/resources/news/hefring-raises-euro-2m-in-funding-to-accelerate-growth): **€2.2m financing led by Faber Ventures**. Page says original €2m target increased. No round-stage label is explicitly established by this release. | | **iLoF** | Optical laser analysis of blood and AI-generated molecular profiles, combining photonics/biophysics with personalised diagnosis and clinical-trial screening. | [EIT Health, 2022-07-28](https://eithealth.eu/news-article/wildcard-winner-ilof-secures-further-5m-investment/) names Faber as lead of seed funding reported as **$5m**. [Company timeline](https://ilof.tech/about) independently lists Faber in its 2022 funding round and an Alzheimer's pilot in 2023 (undated; accessed 2026-10-06). Funding package includes a grant; see conflict below. |
team@apexlogos.ai22 days ago
MATCH

Felix Petersen Faber, partner	$0$0 – $0	Europe
Alejandro Martí Faber, Venture Partner	—— – —
Alexandre Barbosa Faber, Managing Partner	—— – —
Anthony Douglas Faber, External job title; Faber affiliation unverified	—— – —
Bruno Ferreira Faber, Venture Partner	—— – —
Carlos Esteban Faber, Partner	—— – —
Carlos Ferrer Faber, External job title; Faber affiliation unverified	—— – —
Cláudia Soares Faber, External job title; Faber affiliation unverified	—— – —
David Dias Faber, External job title; Faber affiliation unverified	—— – —
Filipa Saldanha Faber, External job title; Faber affiliation unverified	—— – —
Filipe Almeida Faber, External job title; Faber affiliation unverified	—— – —
Gonçalo Serpa Pinto Faber, Investor, ex-Senior Partner McKinsey	—— – —
Henrique Moniz Faber, External job title; Faber affiliation unverified	—— – —
Jaime Jorge Faber, Venture Partner	—— – —
Javier Echarri Faber, Investor	—— – —
João Freitas Faber, External job title; Faber affiliation unverified	—— – —
João Graça Faber, External job title; Faber affiliation unverified	—— – —
João Nuno Magalhães Faber, External job title; Faber affiliation unverified	—— – —
Julián Goméz Faber, Associate	—— – —
Lara Branco Faber, Analyst	—— – —
Liliana Ferreira Faber, External job title; Faber affiliation unverified	—— – —
Marco Alves Faber, External job title; Faber affiliation unverified	—— – —
Marco Costa Faber, External job title; Faber affiliation unverified	—— – —
Margarida Oliveira Faber, Analyst	—— – —
Mário Figueiredo Faber, Venture Partner & Chief Scientist	—— – —
Niklas Koerner Faber, Partner	—— – —
Pedro Bizarro Faber, External job title; Faber affiliation unverified	—— – —
Pedro Saleiro Faber, External job title; Faber affiliation unverified	—— – —
Peter Rive Faber, Investor	—— – —
Rafael Achaerandio Faber, External job title; Faber affiliation unverified	—— – —
Raquel Gaião Silva Faber, Senior Associate	—— – —
Ricardo Calado Faber, External job title; Faber affiliation unverified	—— – —
Rita Matos Faber, Analyst	—— – —
Rita Sousa Faber, Partner	—— – —
Rita Waite Faber, External job title; Faber affiliation unverified	—— – —
Rui Melo de Carvalho Faber, Partner & CFO	—— – —
Sofia Santos Faber, Partner	—— – —
Thomas Childs Faber, Associate	—— – —
Vasco Pedro Faber, External job title; Faber affiliation unverified	—— – —
Virgílio Bento Faber, External job title; Faber affiliation unverified	—— – —

$—2026-09-22	Embodied AI	Faber, Look AI Ventures, Vento, Plug and Play Tech Center, Techshop Capital, Kickfund, Excellis
$21M2026-01-07	Luminate	Austin Walne, Y Combinator, 8VC, LGF, Atlantic Bridge, Metaplanet, SciFounders, Faber
$—2026	ISPTech	Faber
$2M2025-11-24	Ponda	Faber
$—2025-02-20	Zymvol	Faber, Elaia
$—2025-02-06	KOA Biotech	Faber
$—2024-12-17	Meight	Faber
€2M2024-05-21	Hefring Marine	Faber
$—2023-06-20	Vyoma	Faber
$14M2023-05-17	Mitiga Solutions	Faber
$2M2023-02-16	Kern	Faber
$—2022-07-28	iLoF	Faber, Lunar Ventures, Alter Global, M12, Scale Venture Partners, Quiet Capital, re.Mind Capital
$—2022-05-18	Annea	Faber
$—2021-08-27	Abtrace	Faber
$—2021-02-03	Sword Health	Founders Fund, Transformation Capital, Khosla Ventures, Vinod Khosla, Green Innovations, Vesalius Biocapital Partners Sàrl, Faber
$9M2020-02-27	Sword Health	Khosla Ventures, Vinod Khosla, Founders Fund, Green Innovations, Vesalius Biocapital Partners Sàrl, Faber
$—2020	YDATA	Faber
$7M2019-10-08	Codacy	Faber
$2M2019-08-06	EnjoyHQ	Point Nine Capital, Kibo Ventures, Social Capital, Techstars, Phoenix Court Group, TheVentureCity, Faber
$400K2019	Unbabel	Y Combinator, Shilling Capital Partners, Faber
$—2013-07-01	Gleam	Faber
$2MUnknown date	Yplasma	Faber
$—Unknown date	Resoniks	Faber
$—Unknown date	Poseidona	Faber
$—Unknown date	Poseidona	Faber
$—Unknown date	Photon Bridge	Faber
$3MUnknown date	OpNova	Faber
$1MUnknown date	Apres	Faber
$17M2026-01-07	Luminate Medical	Y Combinator, 8VC, Atlantic Bridge, Pareto Holdings, Metaplanet, Elkstone, Faber
€4M2025-01-13	PHOTON IP	Faber
$—Unknown date	MITIGA SOLUTIONS SL	Faber
$2MUnknown date	Annea Ai	Faber

Funds3

Team

Co-investing

Investments